In vitro susceptibility of leishmania donovani to miltefosine in Indian visceral leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 89, Issue 4, 2013, Pages 750-754

  Prajapati, Vijay Kumar ^a,b,c,d   Sharma, Smriti ^a,b,c,d   Rai, Madhukar ^a,b,c,d   Ostyn, Bart ^a,b,c,d   Salotra, Poonam ^a,b,c,d   Vanaerschot, Manu ^a,b,c,d   Dujardin, Jean Claude ^a,b,c,d   Sundar, Shyam ^a,b,c,d  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c SAFDARJUNG HOSPITAL   (India)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MILTEFOSINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; IN VITRO STUDY; LEISHMANIA DONOVANI; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROMASTIGOTE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE;

EID: 84886055716     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0096     Document Type: Article

References (16)

1. Alvar J,Velez ID,HerreroM,DesjeuxP,CanoJ, JaninJ,denBoerM; WHO Leishmaniasis Control Team, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.
2. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD, 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501. (Pubitemid 34826855)
3. Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A, 2008. Can visceral leishmaniasis be eliminated from Asia J Vector Borne Dis 45: 105-111. (Pubitemid 351809286)
4. WHO, 2005. Expert Committee on Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005-2015). New Delhi: WHO regional Office for South-East Asia.
5. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S, 2011. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 66: 874-879.
6. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746. (Pubitemid 35375612)
7. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J, 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-1800.
8. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550.
9. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC, 2013. Increasing failure of Miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 1530-1538.
10. Kumar D, Kulshrestha A, Singh R, Salotra P, 2009. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835-838.
11. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S, 2012. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis-status of newly introduced drugs. Am J Trop Med Hyg 87: 655-657.
12. Kulshrestha A, Bhandari V,Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P, 2013. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res 112: 825-828.
13. Maurya R, Mehrotra S, Prajapati VK, Nylen S, Sacks D, Sundar S, 2010. Evaluation of blood agar microtiter plates for culturing Leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol 48: 1932-1934.
14. Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S, 2010. Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infect Genet Evol 10: 1145-1150.
15. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P, 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6: e1657.
16. Leprohon P, Legare D, Raymond F, Madore E, Hardiman G, Corbeil J, Ouellette M, 2009. Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res 37: 1387-1399.